Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(9):842–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

International Non-Hodgkin’s Lymphoma Prognostic Factors P. A predictive model for aggressive non-hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.

Article  Google Scholar 

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.

Article  CAS  PubMed  Google Scholar 

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dlouhy I, Karube K, Enjuanes A, Salaverria I, Nadeu F, Ramis-Zaldivar JE, Valero JG, Rivas-Delgado A, Magnano L, Martin-Garcia D, et al. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. Br J Haematol. 2022;196(3):589–98.

Article  CAS  PubMed  Google Scholar 

Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–8.

Article  CAS  PubMed  Google Scholar 

Barrington SF, Trotman J. The role of PET in the first-line treatment of the most common subtypes of non-hodgkin lymphoma. Lancet Haematol. 2021;8(1):e80–e93.

Article  CAS  PubMed  Google Scholar 

Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(dagger). Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2021;32(3):404–11.

Article  PubMed  Google Scholar 

Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, Duhrsen U, Ceriani L, Schmitz C, Wiegers SE, Huttmann A et al. Proposed new dynamic prognostic index for diffuse large B-Cell lymphoma: International Metabolic Prognostic Index. J Clin Oncol. 2022:JCO2102063.

Delaby G, Hubaut MA, Morschhauser F, Besson A, Huglo D, Herbaux C, Baillet C. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline (18)F-FDG PET-CT. Leuk Lymphoma. 2020;61(7):1584–91.

Article  CAS  PubMed  Google Scholar 

Zhang X, Chen L, Jiang H, He X, Feng L, Ni M, Ma M, Wang J, Zhang T, Wu S, et al. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022;49(4):1298–310.

Article  CAS  PubMed  Google Scholar 

Jin H, Jin M, Lim CH, Choi JY, Kim SJ, Lee KH. Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment. Front Oncol. 2023;13:1186311.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, Meignan M, Buvat I. (18)F-FDG PET dissemination features in diffuse large B-Cell lymphoma are Predictive of Outcome. J Nucl Med. 2020;61(1):40–5.

Article  PubMed  PubMed Central  Google Scholar 

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.

Article  CAS  PubMed  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.

Article  PubMed  PubMed Central  Google Scholar 

Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29(14):1844–54.

Article  PubMed  Google Scholar 

Metser U, Prica A, Hodgson DC, Mozuraitis M, Eberg M, Mak V, Green B, Singnurkar A, Dudebout J, MacCrostie P, et al. Effect of PET/CT on the management and outcomes of participants with Hodgkin and aggressive Non-Hodgkin Lymphoma: a Multicenter Registry. Radiology. 2019;290(2):488–95.

Article  PubMed  Google Scholar 

Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, Stathis A, Bruno A, Moccia AA, Giovanella L, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv. 2020;4(6):1082–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mikhaeel NG, Smith D, Dunn JT, Phillips M, Moller H, Fields PA, Wrench D, Barrington SF. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129(19):2616–23.

Article  CAS  PubMed  Google Scholar 

Schmitz C, Huttmann A, Muller SP, Hanoun M, Boellaard R, Brinkmann M, Jockel KH, Duhrsen U, Rekowski J. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25–36.

Article  CAS  PubMed  Google Scholar 

Albano D, Treglia G, Dondi F, Calabro A, Rizzo A, Annunziata S, Guerra L, Morbelli S, Tucci A, Bertagna F. (18)F-FDG PET/CT maximum tumor dissemination (Dmax) in lymphoma: a New Prognostic factor? Cancers (Basel). 2023;15(9).

Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, van der Holt B, de Vet HCW, Hoekstra OS, Boellaard R, et al. (18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49(3):932–42.

Article  PubMed  Google Scholar 

Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50.

Article  CAS  PubMed  Google Scholar 

Moreno MJ, Bosch R, Dieguez-Gonzalez R, Novelli S, Mozos A, Gallardo A, Pavon MA, Cespedes MV, Granena A, Alcoceba M, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol. 2015;235(3):445–55.

Article  CAS  PubMed  Google Scholar 

Chen J, Xu-Monette ZY, Deng L, Shen Q, Manyam GC, Martinez-Lopez A, Zhang L, Montes-Moreno S, Visco C, Tzankov A, et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015;6(8):5597–614.

Article  PubMed  PubMed Central  Google Scholar 

Jiang X, Lu X, Gentles AJ, Zhao D, Wander SA, Zhang Y, Natkunam Y, Slingerland J, Reis IM, Rabinovich B, et al. HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins. Blood Adv. 2021;5(23):5072–85.

Article  CAS  PubMed  PubMed Central  Google Scholar